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tolic function were recorded.All had confirmed normal short axis systolic contractility.
Diastolic function was studied by means of tissue doppler.
Results: Echocardiographic indices were predictably abnormal, and plasma MMP-9 &
TIMP-1 were elevated in HT. Within the hypertensive cohort, LV mass and septal thick-
ness correlated positively with TIMP-1 (Ranked Pearson’s correlation r=0.312,p=0.035;
r=0.359,p=0.013 respectively). There was a negative correlation between e’ and TIMP-1
(r= -0.296,p=0.037).
Conclusion: We have defined a novel relationship between elevated TIMP-1, increased
LV mass and impaired diastolic relaxation. This suggests a role for this metalloproteinase
inhibitor in the patho-physiology of hypertensive heart disease potentially related to dias-
tolic heart failure in HT.
1142-187 Three-Dimensional Echocardiographic and Magnetic 
Resonance Assessment of the Effect of Telmisartan 
Compared With Carvedilol on Left Ventricular Mass: A 
Multicenter, Randomized, Controlled Study
Domenico Galzerano, Luca Del Viscovo, Paolo Tammaro, Carlo Tedeschi, Roberto 
Breglio, Diana Lama, Antonio Cerciello, Bernardino Tuccillo, Paolo Capogrosso, San 
Gennaro Hospital, Naples, Italy
Background: Meta-analyses examining hypertensive left ventricular hypertrophy (LVH)
suggest that the observed regression of LVH is related not only to blood pressure control,
but also to drug-related effects.
Objective: To elucidate the efficacy and the effects on left ventricular mass of different
classes of drugs, on the hypothesis that blockade of angiotensin II type 1 (AT1) receptors
by the AT1 receptor antagonist telmisartan (TEL) would reduce left ventricular mass
assessed by three-dimensional echocardiography (3DE) and magnetic resonance imag-
ing (MRI) more than conventional treatment with the beta-blocker carvedilol (CARV).
Design and Methods: This study randomized 80 patients with mild-to-moderate hyperten-
sion plus LVH and optimal acoustic window to receive either TEL 80 mg od or CARV 25
mg od for 40 weeks. Ten patients withdrew from the study because diastolic blood pres-
sure remained above 90 mmHg. At baseline and after the 40-week treatment, blood
tests, 3DE and 24-h ABPM were performed. 28 patients underwent MRI.
RESULTS: Systolic and diastolic blood pressure reductions were similar in both treat-
ment groups(before and after TEL: 160±9.5and 97.8±5.8 vs 128±6.5/77.3±5.4 mmHg;
CARV: 160±10.7 and 95.4±4.9 vs 128.4±4.9 and 78.3±4.8 mmHg). Both TEL (P<0.001)
and CARV (P<0.01) progressively reduced left ventricular mass index by 22 and 12 g/m2
(15% and 9%), respectively, at week 40 (P=0.02). A higher percentage of normalized left
ventricular mass was achieved in the TEL group (44% vs 30%).
CONCLUSIONS: TEL produced a greater reduction of left ventricular mass than CARV,
suggesting that AT1 receptor blockade provides an important mechanism, beyond that of
lowering blood pressure, in the regression of left ventricular mass in hypertensive
patients.
1142-188 Pulse Wave Velocity Measured by Complior Method in a 
Brazilian Young Population Followed-Up for a 13 Year-
Period: The Rio de Janeiro Study
Oswaldo Pizzi, Roberto Pozzan, Andréa Brandão, Maria Eliane Magalhães, Elizabete 
Freitas, Ayrton Brandão, State University of Rio de Janeiro, Rio de Janeiro, Brazil, 
Medical School of Petrópolis, Petrópolis, Brazil
Background: Vascular injury in youth associated to early blood pressure (BP) alterations
and other risk factors is not well known. To establish their possible association, pulse
wave velocity (PWV), clinical, metabolic and haemodynamic variables were measured in
young adults stratified by their blood pressure percentile obtained 13 years earlier.
Methods: 385 young subjects (201M) were evaluated at their schools in 1987-88
(12.74±1.65 y). BP was measured 3 times, and the third measure was used for analysis.
Body mass index (BMI) was obtained. In 1997-2000 (21,91±2,12 y), they were examined
at the hospital. BP, BMI, waist and hip were obtained and cholesterol (C), tryglicerides,
LDL-C, HDL-C, creatinine, plasma glucose and insulin were measured after a 12h fast-
ing. A sample of 60 young adults underwent PWV measurement by Complior method
and was stratified according to their former (at school) BP percentile: Group 1 < 50th per-
centile (n=25, 11 M) and Group 2 > 95th percentile (n=35, 19 M).
Results: 1) Group 1 had higher age (p<.05) and all comparisons were adjusted for age.
2) Group 2 had higher weight (p<.05), systolic BP (SBP) (p<.03), diastolic BP (DBP)
(p<.02), mean BP (MBP) (p<.02), PWV (p<.03), fasting glucose (p<.03) and lower HDL-C
(p<.03). 3) PWV correlated positively and significantly with SBP (r=0.333, p<.02), MBP
(r=0.303, p<.02) and heart rate (HR) (r=0.284, p<.03) obtained 13 years earlier. 4) PWV
showed significant correlations with the following current variables: weight (r=0.403,
p<.01), height (r=0.301, p<.02), waist circumference (r=0.347, p<0.01), waist/hip ratio
(r=0.328, p=0.01), SBP (r=0.444, p<.01), DBP (r=0.318, p<.02), pulse pressure (PP)
(r=0.274, p<.04), MBP (r=0.424, p<.01) and serum creatinin (r=0.400, p<.01). 5) In co-
variance analysis, when PWV was adjusted for current SBP, DBP, MBP and PP, no signif-
icant differences were observed between the groups, although group 2 showed higher
means in all comparisons.
Conclusion: High BP percentile obtained in adolescence was associated with higher BP
and PWV 13 years later. These results suggest that early vascular changes could be
identified in young and emphasize that primary prevention must begin early in life.
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847-1 Constellation of Risk Variables of Metabolic Syndrome 
at Low Levels in Childhood Is Beneficially Associated 
With Adulthood Cardiovascular Risk: The Bogalusa 
Heart Study
Wei Chen, Sathanur R. Srinivasan, Shengxu Li, Jihua Xu, Gerald S. Berenson, Tulane 
University Health Sciences Center, New Orleans, LA
Background: Most epidemiologic studies have focused on the association between the
adverse levels of risk variables of metabolic syndrome and the risk of cardiovascular (CV)
disease. However, information is lacking on the relation of metabolic syndrome risk vari-
ables clustering at favorable levels in childhood and CV disease risk in adulthood.
Methods: The study cohort (n=1,474) was examined in childhood (4-17 years) and again
in adulthood (18-41 years), with an average follow-up period of 15.8 years in a black-
white community. The childhood criterion metabolic syndrome variables included the low-
est quartiles (specific for age, race, sex and study year) of body mass index, homeostasis
model assessment of insulin resistance, systolic blood pressure and total cholesterol/
high-density lipoprotein cholesterol ratio. The measures of CV risk in adulthood included
prevalence of metabolic syndrome, parental histories of CV disease, and carotid artery
intima-media thickness (IMT) measured in a subsample (n=138).
Results: In childhood, 9% of the cohort displayed clustering of 3 or 4 criterion risk vari-
ables at the bottom quartiles, which was significantly higher than expected by chance
alone (P<0.01). These children, compared with those without any risk variables at the
bottom quartiles, had a lower prevalence of metabolic syndrome in adulthood (2.3% vs
20.0%, P<0.001). In addition to lower odds for having metabolic syndrome in adulthood
(11-fold, P<0.001), they also displayed lower odds for having parental histories of CHD
(1.9-fold, P=0.039), hypertension (1.5-fold, P=0.045 ) and type 2 diabetes (1.6-fold,
P=0.079). Mean values of carotid IMT in adulthood decreased with an increasing number
of risk variables clustering at the bottom quartiles in childhood (P for trend=0.013).
Conclusion: The constellation of metabolic syndrome variables at low levels in child-
hood is associated with lower measures of CV risk in adulthood. The beneficial conse-
quence of such a lifetime low-risk profile in youth reinforces the importance of CV
disease health promotion and life style modification in early life.
2:15 p.m.
847-2 Combination Aspirin and Statin Therapy Markedly 
Reduces C-Reactive Protein Levels in a High-Risk 
Population Without Coronary Disease
Marlene S. Williams, Lewis C. Becker, Taryn F. Moy, Lisa R. Yanek, Nauder Faraday, 
Diane M. Becker, Johns Hopkins Medical Institution, Baltimore, MD
Background: There remains controversy about the anti-inflammatory effects of both low
dose aspirin (ASA) (81mg) therapy and statins and little is known of their combined
effect. This study was designed to determine the extent to which chronic low dose ASA
therapy, statin therapy, and combined statin and ASA therapy have an anti-inflammatory
effect as determined by plasma levels of high sensitivity C-reactive protein (hs-CRP) in a
high-risk population without coronary artery disease (CAD). Methods: We examined 699
asymptomatic siblings (SIBS) of probands with documented CAD < 60 years of age.
SIBS were 49.0 ± 8 years of age, 59% African American, and 41% male and were not
using regular nonsteroidal or other anti-inflammatory agents. Plasma levels of hs-CRP
were measured by ELISA. Three separate multivariate regression models were used,
one each for the use of ASA alone, statins alone, and combination therapy, each control-
ling for age, sex, race, systolic blood pressure, LDL-cholesterol, smoking, diabetes, and
body mass index. Each model contained only people using the specific therapy of inter-
est, plus nonusers. Results: Lower levels of hs-CRP were observed in individuals using
ASA alone (N=23) hs-CRP= 2.1± 1.8 µg/ml, statins alone(N=56) hs-CRP=2.8± 2.6 µg/ml,
and the combination of both statins and ASA(N=13) hs-CRP=1.4± 1.4 µg/ml, in compari-
son with nonusers (N=607) hs-CRP=3.1± 3.0 µg/ml. Combined therapy was the stron-
gest independent predictor of lower hs-CRP levels (p=0.0008). For people using statins
alone, the multivariate adjusted significance was lower, (p=0.007), and for people using
Differences between controls and hypertensives
Controls (n=24) Hypertensives (n=52) p-value
SBP 127(16) 154(22) <0.0001
DBP 79(10) 90(13) <0.001
Cholesterol (mmol/l) 5.7 (5.1-6.1) 5.2 (4.8-6.1) 0.33
LV mass (gm) 182 (68) 231 (85) 0.009
IVRT (msec) 110(99-130) 122(106-143 0.39
E-wave(cm/sec) 0.73(0.15) 0.81(0.02) 0.03
A-wave (cm/sec) 0.67(0.03) 0.83(0.02) <0.001
e' wave(cm/sec) 0.1(0.078-0.12) 0.08(0.07-0.1) 0.009
e'/a' 7.4(2.2) 9.2(2.5) 0.002
MMP-9 42(35-103) 70(45-135) 0.029
TIMP-1 290(230-350) 380(273-580) 0.005
